Skip to main content
Signal8
Launch Terminal

Dianthus Therapeutics, Inc. /DE/ (DNTH)

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Dianthus Therapeutics, Inc. logo

Dianthus Therapeutics, Inc.

NASDAQ:DNTHHealthcare
-0.39%$82.38
AH$82.38+0.00%vs close
Mkt Cap$4.61B
Float48.79M
O/S55.93M
Vol
$ Vol
RVOL
Inst Own-
SI18.4%
Earnings
Dilution
Dianthus Therapeutics, Inc. logoNASDAQ:DNTH$82.38-0.39%
Phase Distribution
12 lead-sponsored trials·7 active·2 completed
Phase 11
Phase 23
Phase 32
Not applicable6
Status Overview
Recruiting4
Active, not recruiting3
Completed2
Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Recruiting

    A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

    Claseprubart, Claseprubart

    Chronic Inflammatory Demyelinating Polyneuropathy

    Enrollment
    256
    Start
    Feb 2025
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2030est.
    NCT06858579
  • Phase 3
    Recruiting

    A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

    Claseprubart, Placebo

    Myasthenia Gravis, Generalized

    Enrollment
    195
    Start
    Jun 2026
    Primary Completion
    Dec 2028est.
    Completion
    Sep 2031est.
    NCT07647510
  • Phase 2
    Completed

    MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

    MGTA-456

    Inherited Metabolic Disorders (IMD)

    Enrollment
    8
    Start
    Feb 2018
    Primary Completion
    Feb 2020
    Completion
    Jan 2021
    NCT03406962
  • Phase 2
    Active, not recruiting

    A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

    Claseprubart, Placebo

    Myasthenia Gravis, Generalized

    Enrollment
    65
    Start
    Feb 2024
    Primary Completion
    Jul 2025
    Completion
    Oct 2028est.
    NCT06282159
  • Phase 2
    Active, not recruiting

    A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

    Claseprubart, Placebo

    Multifocal Motor Neuropathy

    Enrollment
    46
    Start
    Sep 2024
    Primary Completion
    Dec 2026est.
    Completion
    Mar 2028est.
    NCT06537999
  • Phase 1
    Terminated

    Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

    MGTA-117

    Acute Myeloid Leukemia, Myelodysplasia

    Enrollment
    22
    Start
    Feb 2022
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT05223699
  • Not applicable
    Terminated

    Clinical Evaluation of the TRVD™ System in ADHF

    TRVD Therapy

    Acute Heart Failure, Congestive Heart Failure +1

    Enrollment
    13
    Start
    Aug 2015
    Primary Completion
    Apr 2019
    Completion
    May 2019
    NCT03621436
  • Observational
    Terminated

    A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456

    Safety and efficacy assessments

    Inherited Metabolic Disorders (IMD)

    Enrollment
    3
    Start
    May 2019
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT04008849
  • Not applicable
    Completed

    Magenta Elevate™ EFS in High-Risk PCI Patients

    The Elevate™ System

    High-risk Percutaneous Coronary Intervention

    Enrollment
    18
    Start
    May 2023
    Primary Completion
    Dec 2023
    Completion
    Jan 2024
    NCT05727059
  • Not applicable
    Active, not recruiting

    Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients

    The Elevate™ System

    High-Risk Percutaneous Coronary Intervention

    Enrollment
    20
    Start
    Dec 2020
    Primary Completion
    Jun 2026est.
    Completion
    Jun 2026est.
    NCT06099548
  • Not applicable
    Recruiting

    ELEVATE High-Risk PCI Pivotal Study

    Elevate, Impella

    High-Risk Percutaneous Coronary Intervention (High-risk PCI)

    Enrollment
    290
    Start
    Jul 2025
    Primary Completion
    Mar 2027est.
    Completion
    Sep 2027est.
    NCT07001332
  • Not applicable
    Recruiting

    Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

    Elevate™ System

    Cardiogenic Shock, Heart Failure +1

    Enrollment
    10
    Start
    Nov 2025
    Primary Completion
    Jan 2028est.
    Completion
    Feb 2028est.
    NCT07293923
Search ClinicalTrials.gov for “Dianthus Therapeutics”